Adverse drug reaction deaths reported in United States vital statistics, 1999-2006
- PMID: 22253191
- DOI: 10.1345/aph.1P592
Adverse drug reaction deaths reported in United States vital statistics, 1999-2006
Abstract
Background: Adverse drug reactions (ADRs) are an important source of morbidity and mortality during medical care.
Objective: To examine the trends in mortality related to ADRs reported through the US vital statistics system since January 1999.
Methods: Demographic characteristics of people reported as dying as a result of ADRs from 1999 to 2006 were evaluated. The National Mortality Statistics database was queried for International Classification of Diseases, Tenth Revision, codes Y40-Y59, which are specific for deaths due to adverse effects of drugs in therapeutic use. The data were subgrouped based on demographic factors to identify important trends. Crude rates were calculated based on incidents per 100,000 population. Odds ratios and 95% confidence intervals for subgroups were calculated by logistical regression.
Results: During the 8-year study period 2,313,902,748 person years were evaluated and 2341 ADR-related deaths were identified. Annual rates ranged from 0.08/100,000 to 0.12/100,000, and rates increased significantly over time at a rate of 0.0058 per year. ADR deaths were significantly more likely in persons older than 55 years. The risk was greatest in those aged 75 years or older (OR 6.96, 95% CI 6.30 to 7.69). ADR deaths were higher among men than women. Rates varied by race and ethnicity and were highest among blacks (OR 1.38, 95% CI 1.23 to 1.54). Geographically, rates varied widely between states. Based on urbanization, rates were highest in extremely rural (non-core) areas (OR 2.05, 95% CI 1.76 to 2.38). The most common drug classes associated with death were anticoagulants, opioids, and immunosuppressants.
Conclusions: ADR death rates have a clear association with age, race, and urbanization subgroups. Older individuals, males, blacks, and individuals residing in extremely rural areas experienced higher ADR death rates; these findings warrant further study to develop prevention strategies.
Similar articles
-
Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.J Manag Care Pharm. 2012 Jul-Aug;18(6):427-38. doi: 10.18553/jmcp.2012.18.6.427. J Manag Care Pharm. 2012. PMID: 22839683 Free PMC article.
-
Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.Drug Saf. 2011 Aug 1;34(8):669-82. doi: 10.2165/11591730-000000000-00000. Drug Saf. 2011. PMID: 21751827
-
CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.MMWR Suppl. 2014 Oct 31;63(4):3-27. MMWR Suppl. 2014. PMID: 25356673
-
Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.Drug Saf. 2012 Dec 1;35(12):1171-82. doi: 10.1007/BF03262002. Drug Saf. 2012. PMID: 23072620
-
Heart Disease Death Rates Among Blacks and Whites Aged ≥35 Years - United States, 1968-2015.MMWR Surveill Summ. 2018 Mar 30;67(5):1-11. doi: 10.15585/mmwr.ss6705a1. MMWR Surveill Summ. 2018. PMID: 29596406 Free PMC article.
Cited by
-
Pharmacist medication review: An integrated team approach to serve home-based primary care patients.PLoS One. 2021 May 25;16(5):e0252151. doi: 10.1371/journal.pone.0252151. eCollection 2021. PLoS One. 2021. PMID: 34033661 Free PMC article. Review.
-
Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients.J Pers Med. 2021 Dec 10;11(12):1343. doi: 10.3390/jpm11121343. J Pers Med. 2021. PMID: 34945816 Free PMC article.
-
Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria.Int J Clin Pharm. 2019 Aug;41(4):1062-1073. doi: 10.1007/s11096-019-00849-9. Epub 2019 May 28. Int J Clin Pharm. 2019. PMID: 31140162
-
Mimicking the Endothelium: Dual Action Heparinized Nitric Oxide Releasing Surface.ACS Appl Mater Interfaces. 2020 May 6;12(18):20158-20171. doi: 10.1021/acsami.9b22277. Epub 2020 Apr 22. ACS Appl Mater Interfaces. 2020. PMID: 32271542 Free PMC article.
-
Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds.Front Pharmacol. 2021 Jul 26;12:713178. doi: 10.3389/fphar.2021.713178. eCollection 2021. Front Pharmacol. 2021. PMID: 34381365 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials